Europe Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other Consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Application (Oncological, Non-Oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Country, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

The Europe Liquid Biopsy Market was valued at USD 1.16 Billion in 2024 and is expected to reach USD 1.86 Billion by 2030 with a CAGR of 11.72%. The Europe Liquid Biopsy Market is witnessing robust growth driven by the increasing demand for non-invasive diagnostic methods and the rising burden of cancer cases across the region. Liquid biopsy has emerged as a promising alternative to traditional tissue biopsies, offering real-time insights into tumor genetics with minimal discomfort for patients. As awareness of early cancer detection and precision medicine continues to grow, healthcare providers are increasingly adopting liquid biopsy for its ability to monitor disease progression and treatment response without requiring repeated invasive procedures. The rise in government and private funding towards cancer research and diagnostics has further supported the development and commercialization of advanced liquid biopsy technologies across Europe.

The market is being propelled by strong drivers such as technological advancements in circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosome analysis. These innovations are improving the sensitivity, specificity, and reliability of liquid biopsy tests, making them more suitable for early detection, prognosis, and therapeutic decision-making. Personalized treatment strategies are gaining momentum, and liquid biopsy plays a crucial role by enabling oncologists to tailor therapies based on real-time tumor profiles. Moreover, the growing use of liquid biopsy in clinical trials and drug development is accelerating its adoption across both research and clinical settings. The increased focus on multi-cancer early detection tests and integration of artificial intelligence for data interpretation are shaping the future of the market.

Despite the promising outlook, the Europe Liquid Biopsy Market faces several challenges. High costs associated with liquid biopsy tests and limited reimbursement coverage are restricting accessibility for patients in certain healthcare systems. Regulatory complexities around the validation and approval of new diagnostic technologies are causing delays in commercialization. Variability in test accuracy across different platforms and cancer types also raises concerns about clinical reliability. Lack of standardized protocols for test administration and result interpretation remains a barrier to widespread clinical integration. Educating clinicians and expanding infrastructure to support high-throughput testing will be essential for overcoming these limitations and ensuring the long-term growth of the market.

Key Market Drivers

Rising Incidence of Cancer

​The rising incidence of cancer in Europe is a significant driver of the liquid biopsy market, underscoring the need for advanced, non-invasive diagnostic tools. In 2022, Europe recorded approximately 4.47 million new cancer cases, with an age-standardized rate (ASR) of 280 per 100,000 individuals. The cumulative risk of developing cancer by age 75 was 27.9%, highlighting the widespread impact of the disease across the continent. ​

This escalating cancer burden has intensified the demand for innovative diagnostic solutions. Liquid biopsy, which analyzes biomarkers in bodily fluids like blood, offers a non-invasive alternative to traditional tissue biopsies. It enables early detection, monitoring of treatment efficacy, and detection of minimal residual disease, all crucial for personalized cancer management. The ability to detect genetic mutations and alterations in real-time allows clinicians to tailor treatments to individual patients, improving outcomes and reducing unnecessary procedures.​

As the prevalence of cancer continues to rise, the adoption of liquid biopsy technologies is expected to grow, driven by their potential to enhance diagnostic accuracy and patient care. This trend is particularly evident in countries with advanced healthcare systems and a focus on personalized medicine, where liquid biopsy is increasingly integrated into routine clinical practice.

Rising Investment in Cancer Diagnostics

​The Europe Liquid Biopsy Market is experiencing significant growth, primarily driven by substantial investments in cancer diagnostics. In 2022, Europe recorded approximately 2.74 million new cancer cases, marking a 2.3% increase from 2020. This escalating cancer burden has prompted both public and private sectors to allocate increased funding toward innovative diagnostic solutions, including liquid biopsy technologies.​

Governments are channeling resources into national cancer programs, aiming to enhance early detection and treatment outcomes. For instance, the European Commission's EU4Health program has earmarked funds to improve cancer screening and data collection across member states. Concurrently, private entities are investing in the development of advanced diagnostic tools. In 2025, the European Investment Bank financed Universal DX with USD 22.75 Million to develop blood-based tests for early cancer detection.​

These investments are fostering the advancement of liquid biopsy technologies, which offer non-invasive, accurate, and cost-effective means for early cancer detection and monitoring. As a result, liquid biopsy is becoming an integral component of personalized medicine strategies, enabling tailored treatment plans and improving patient outcomes. The continued financial support and focus on innovation are expected to propel the growth of the liquid biopsy market in Europe throughout the forecast period.

Technological Advancements

Technological advancements are playing a transformative role in shaping the Europe Liquid Biopsy Market by significantly enhancing diagnostic accuracy, speed, and clinical relevance. One of the most impactful innovations is the refinement of next-generation sequencing (NGS) technologies, which allow for high-throughput analysis of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and exosomal RNA. These platforms can identify even low-frequency genetic alterations, enabling earlier cancer detection and more accurate disease monitoring. As sequencing becomes faster and more cost-efficient, its clinical integration has accelerated, creating broader adoption across oncology practices.

Artificial intelligence (AI) and machine learning (ML) are also revolutionizing the interpretation of liquid biopsy data. These tools are improving biomarker identification, predictive modeling, and treatment decision-making by analyzing complex genomic data in real time. AI-driven platforms reduce turnaround times and improve diagnostic precision, making liquid biopsy an increasingly attractive option for oncologists and researchers.

In Europe, rapid digitalization of healthcare systems and the growth of precision medicine initiatives have encouraged partnerships between diagnostic companies and research institutions to develop more reliable and non-invasive testing methods. For example, multi-analyte liquid biopsy platforms that combine genetic, epigenetic, and proteomic data are gaining traction for comprehensive cancer profiling.

Recent studies from European academic centers highlight that technological improvements have led to a more than 40% increase in detection sensitivity for certain solid tumors using liquid biopsy over the past two years. This demonstrates a strong correlation between innovation and improved patient outcomes. As these technologies continue to mature and gain regulatory support, liquid biopsy is expected to move beyond niche use cases and become a core component of standard cancer diagnostic protocols throughout Europe.

Download Free Sample Report

Key Market Challenges

High Cost of Liquid Biopsy Tests

The high cost of liquid biopsy tests is a significant challenge impacting the growth and accessibility of the Europe Liquid Biopsy Market. These tests often involve advanced technologies such as next-generation sequencing (NGS), digital PCR, and multi-omics analysis, all of which require specialized equipment, skilled professionals, and complex laboratory infrastructure. The costs are further elevated when multiple biomarkers are analyzed simultaneously, as is common in comprehensive cancer profiling. For healthcare systems under financial pressure and patients without robust insurance coverage, the expense associated with liquid biopsy becomes a barrier to widespread clinical adoption.

Reimbursement limitations compound this issue across several European countries. While some nations have begun integrating liquid biopsy into national healthcare guidelines, coverage is not uniform, and reimbursement policies vary widely. This lack of harmonization results in inconsistent access to these diagnostic tools. In some cases, clinicians may hesitate to recommend liquid biopsy due to concerns that the patient may not be able to afford it or that insurers will not approve the test, particularly for early-stage or asymptomatic patients.

Private laboratories and diagnostics companies also face cost burdens when scaling operations due to the need for constant technological upgrades and stringent quality control requirements. These costs are often passed on to the end-user, limiting the test's affordability. While innovation is driving the market forward, the economics of liquid biopsy remain a significant obstacle in democratizing its benefits. High costs restrict usage primarily to specialized oncology centers or clinical trials, rather than making it a standard diagnostic option across diverse healthcare settings.

Regulatory and Approval Complexities

Regulatory and approval complexities present a major challenge to the growth of the Europe Liquid Biopsy Market. Liquid biopsy technologies often involve cutting-edge platforms that combine molecular diagnostics, bioinformatics, and advanced sequencing—each of which must meet rigorous standards before being approved for clinical use. In Europe, diagnostic tests fall under the In Vitro Diagnostic Regulation (IVDR), a legislative framework that became fully applicable in May 2022. While designed to improve the safety and efficacy of diagnostics, the IVDR has significantly increased the burden of compliance for companies developing and marketing liquid biopsy solutions.

Manufacturers are now required to provide extensive clinical evidence, conduct performance evaluations, and undergo third-party assessments before receiving CE marking for new tests. This has led to delays in the introduction of novel liquid biopsy products, as companies must allocate substantial resources and time to navigate these requirements. Smaller firms in particular often lack the regulatory expertise or funding to manage the complex validation and documentation processes, stalling innovation and limiting competition.

Discrepancies in the interpretation and implementation of regulations across different EU member states create further complications. National regulatory bodies may have varying expectations, leading to inconsistencies in approvals and market access. These delays can reduce the clinical utility of liquid biopsy technologies, especially in cases where early adoption is crucial for patient outcomes. Regulatory uncertainty also discourages investment in the sector, as companies face unpredictable timelines and high entry barriers.

As liquid biopsy tests continue to evolve rapidly, the regulatory environment must also adapt to keep pace with innovation. Without clear, harmonized pathways for approval, the deployment of these transformative diagnostics across Europe may be significantly slowed, affecting both market expansion and patient access to early, non-invasive cancer detection tools.

Key Market Trends

Integration of Liquid Biopsy with Companion Diagnostics

The integration of liquid biopsy with companion diagnostics is emerging as a significant trend in the Europe Liquid Biopsy Market, reshaping how cancer is diagnosed, monitored, and treated. Companion diagnostics are tests designed to identify patients most likely to benefit from a specific therapy by detecting biomarkers associated with treatment response. When combined with liquid biopsy, these diagnostics become more accessible, non-invasive, and suitable for continuous monitoring. This synergy is particularly valuable in precision oncology, where tailoring treatments based on a patient’s genetic profile can improve therapeutic outcomes and reduce unnecessary exposure to ineffective drugs.

The growing demand for targeted therapies in Europe has accelerated the adoption of liquid biopsy-based companion diagnostics. Pharmaceutical companies are increasingly collaborating with diagnostics firms to co-develop drugs and biomarker-based tests as part of a unified treatment strategy. These integrated solutions are being used during clinical trials and in post-market surveillance to evaluate patient responses and adapt treatment plans in real time.

European regulatory bodies and healthcare providers are supporting this integration due to its potential to enhance treatment efficacy and reduce long-term costs associated with trial-and-error prescribing. The ability to track resistance mutations and monitor tumor evolution through liquid biopsy further reinforces its value in companion diagnostic platforms. As a result, this trend is expected to play a crucial role in the mainstreaming of precision medicine across Europe, ensuring that patients receive the most effective therapies based on dynamic molecular insights rather than static tissue biopsies alone.

Focus on Early Detection and Minimal Residual Disease Monitoring

A growing focus on early cancer detection and minimal residual disease (MRD) monitoring is shaping the trajectory of the Europe Liquid Biopsy Market. Early detection of cancer significantly improves patient survival rates and treatment outcomes, but traditional diagnostic tools often miss malignancies at their initial stages. Liquid biopsy offers a non-invasive and highly sensitive method for identifying cancer-associated genetic alterations in blood samples, even before symptoms appear or tumors are visible through imaging. This capability is being increasingly recognized in national cancer screening programs and clinical guidelines across Europe.

Minimal residual disease monitoring is another crucial application gaining traction. After primary treatment such as surgery or chemotherapy, a small number of cancer cells may remain undetected, posing a risk for relapse. Liquid biopsy allows clinicians to detect these traces of disease long before clinical symptoms or imaging results indicate recurrence. This enables timely intervention, personalized follow-up strategies, and reduced reliance on more invasive or expensive diagnostic methods.

Leading research institutions and hospitals in Europe are actively integrating liquid biopsy into longitudinal patient monitoring protocols, particularly in hematological malignancies and solid tumors such as breast, lung, and colorectal cancers. As technologies advance, the sensitivity of MRD detection continues to improve, offering oncologists real-time insights into treatment efficacy and patient prognosis. The ability to monitor disease progression with such precision positions liquid biopsy as a transformative tool in proactive oncology care across Europe.

Segmental Insights

Offering Insights

Based on the Offering, Testing Services emerged as the dominant segment in the Europe Liquid Biopsy Market in 2024. This is due to the growing demand for diagnostic tools that offer non-invasive, accurate, and timely cancer detection. Liquid biopsy testing services are central to the market as they provide a comprehensive solution for analyzing biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood samples. These services are crucial for early cancer detection, monitoring treatment efficacy, detecting minimal residual disease (MRD), and identifying genetic mutations that guide personalized therapy. The increasing adoption of liquid biopsy as a diagnostic tool in oncology is a key factor driving the dominance of testing services. Healthcare providers and research institutions in Europe are increasingly relying on liquid biopsy testing services due to their ability to offer quicker, less invasive alternatives to traditional biopsy methods.

Application Insights

Based on the Application, Oncological emerged as the dominant segment in the Europe Liquid Biopsy Market in 2024. This is driven by the growing recognition of liquid biopsy as a transformative tool in cancer diagnosis and management. Liquid biopsy enables the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers in blood or other bodily fluids, providing valuable insights into the genetic makeup of tumors without the need for invasive tissue biopsies. This non-invasive nature of liquid biopsy has positioned it as a preferred diagnostic method for oncology, especially for early detection, monitoring treatment response, and assessing minimal residual disease (MRD). The increasing cancer burden across Europe, particularly for cancers like lungs, breast, prostate, and colorectal cancer, has fueled the demand for advanced diagnostic tools that can offer earlier, more accurate detection. Liquid biopsy's ability to monitor tumor evolution, predict relapse, and track treatment effectiveness makes it indispensable in oncology.

Download Free Sample Report

Country Insights

Germany emerged as the dominant country in the Europe Liquid Biopsy Market in 2024. This is due to several factors that position it at the forefront of medical technology and innovation. Germany is renowned for its robust healthcare system and commitment to integrating advanced diagnostic technologies. The country’s well-established research infrastructure and strong presence of biotechnology and pharmaceutical companies contribute to its leadership in the adoption of liquid biopsy solutions. Germany’s healthcare system is highly efficient, with a focus on personalized medicine and early cancer detection, which directly aligns with the benefits offered by liquid biopsy technologies. The presence of major research institutions and hospitals in Germany, which are actively involved in clinical trials and the development of liquid biopsy techniques, has further accelerated the market's growth.

Recent Developments

• In April 2025, Precision for Medicine announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services. The collaboration involves integrating the SOPHiA DDM Platform to support clinical trial assays, patient stratification, and data analysis. Leveraging AI-driven algorithms, the platform will analyze complex multimodal data—genomic, radiomic, and clinical—to accelerate clinical trial design and improve precision medicine applications in oncology, rare diseases, and genetic disorders.
• In February 2025, Foresight Diagnostics announced an expanded collaboration with Allogene Therapeutics to develop its minimal residual disease (MRD) assay as a companion diagnostic for identifying large B-cell lymphoma (LBCL) patients eligible for cema-cel treatment in the ALPHA3 clinical trial. The partnership supports MRD assay development across the EU, UK, Canada, and Australia, aiding Allogene’s pivotal trial of cema-cel as a first-line therapy. Patients in remission but MRD-positive, identified via Foresight’s CLARITY IUO assay, may receive a one-time dose of cema-cel to reduce relapse risk.
• In February 2025, Dxcover Limited, a clinical-stage diagnostics company specializing in early cancer detection through its MOSA-Dx platform, announced the closing of a USD 6.2 million funding round to support innovation and commercial expansion. This brings the company’s total funding to USD 21.4 million since its 2019 spinout from the University of Strathclyde.
• In November 2024, Mursla Bio was invited to join EVEREST, a leading European consortium focused on advancing extracellular vesicle (EV) research and clinical applications. The consortium includes 22 institutions and over 80 Marie Curie fellows across 11 countries. Mursla Bio, recognized for its leadership in EV-based diagnostics, will oversee the ‘scaling and commercialization’ work package and contribute to the development of clinical diagnostic solutions. The company will also facilitate researcher exchanges and staff secondments within the consortium.

Key Market Players

• QIAGEN N.V.
• Epigenomics AG
• Inivata Ltd.
• Sysmex Inostics GmbH
• Stilla Technologies
• Novigenix SA
• Eurofins Genomics Europe
• Chronix Biomedical GmbH
• Genseq Ltd.
• Blueberry Therapeutics Ltd.

Report Scope:

In this report, the Europe Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Europe Liquid Biopsy Market, By Offering:

o   Testing Services

o   Kits

o   Platform

o   Other Consumables

• Europe Liquid Biopsy Market, By Technology:

o   Polymerase Chain Reaction (PCR)

o   Next Generation Sequencing (NGS)

o   Others

• Europe Liquid Biopsy Market, By Application:

o   Oncological

o   Non-Oncological

• Europe Liquid Biopsy Market, By End User:

o   Clinical Laboratories

o   Academic & Research Institutes

o   Pharmaceutical & Biotechnology Companies

• Europe Liquid Biopsy Market, By Country:

o   Germany

o   France

o   United Kingdom

o   Italy

o   Spain

o   Russia

o   Poland

o   Bulgaria

o   Finland

o   Portugal

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Europe Liquid Biopsy Market.

Available Customizations:

Europe Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Europe Liquid Biopsy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com